News | September 04, 2007

CE Mark Approves Transcatheter Heart Valve

September 5, 2007 - Edwards Lifesciences Corp. announced that it has received CE Mark approval for European commercial sales of its Edwards SAPIEN transcatheter aortic heart valve technology with the RetroFlex transfemoral delivery system.
The Edwards SAPIEN transcatheter heart valve is implanted via a minimally-invasive procedure, without requiring open-heart surgery. The valve is designed to treat patients with severe aortic heart valve stenosis (a narrowing of the valve that restricts blood flow), who are considered to be high-risk or non-operable for conventional open-heart valve replacement surgery.
The Edwards SAPIEN transcatheter heart valve integrates balloon-expandable stent technology that leverages the company’s proprietary bovine pericardial tissue. With the RetroFlex transfemoral delivery system, the Edwards SAPIEN valve is compressed onto the balloon to the approximate diameter of a pencil and threaded through the patient’s circulatory system from the leg and expanded into place directly over the diseased aortic valve.

For more information: www.edwards.com

Related Content

Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
The Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May.

The Edwards Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May, becoming the first transcatheter tricuspid repair device to be approved in the world.

Feature | Heart Valve Technology | August 21, 2018 | Jeff Zagoudis
The tricuspid valve has been dubbed “the forgotten valve” by many practitioners in the interventional cardiology spac
Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Overlay Init